China Accepts Anke Biotech's Clinical Trial Application for Tumor Drug

MT Newswires Live09-22 14:45

Anhui Anke Biotechnology (Group) (SHE:300009) has won approval from China's National Medical Products Administration (NMPA) to carry out clinical trials for its AK2405 drug for injection, according to a Monday filing with the Shenzhen bourse.

The injection is a HER2-targeting antibody-drug conjugate (ADC), which has an antibody component that specifically binds to the target antigen on the surface of tumor cells.

The product is classified under Registration Category 1 for therapeutic biological products and is used to treat advanced malignant solid tumors.

The company said preclinical studies showed high specificity and anti-tumor activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2669311914?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 14:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669311914","market":"nz","top_or_hot":-1,"title":"China Accepts Anke Biotech's Clinical Trial Application for Tumor Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/300009\">Anhui Anke Biotechnology</a> (Group) (SHE:300009) has won approval from China's National Medical Products Administration (NMPA) to carry out clinical trials for its AK2405 drug for injection, according to a Monday filing with the Shenzhen bourse.</p><p>The injection is a HER2-targeting antibody-drug conjugate (ADC), which has an antibody component that specifically binds to the target antigen on the surface of tumor cells.</p><p>The product is classified under Registration Category 1 for therapeutic biological products and is used to treat advanced malignant solid tumors.</p><p>The company said preclinical studies showed high specificity and anti-tumor activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Accepts Anke Biotech's Clinical Trial Application for Tumor Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Accepts Anke Biotech's Clinical Trial Application for Tumor Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-22 14:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/300009\">Anhui Anke Biotechnology</a> (Group) (SHE:300009) has won approval from China's National Medical Products Administration (NMPA) to carry out clinical trials for its AK2405 drug for injection, according to a Monday filing with the Shenzhen bourse.</p><p>The injection is a HER2-targeting antibody-drug conjugate (ADC), which has an antibody component that specifically binds to the target antigen on the surface of tumor cells.</p><p>The product is classified under Registration Category 1 for therapeutic biological products and is used to treat advanced malignant solid tumors.</p><p>The company said preclinical studies showed high specificity and anti-tumor activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2669311914","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669311914","pubTimestamp":1790059546,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Anhui Anke Biotechnology   has won approval from China's National Medical Products Administration  to carry out clinical trials for its AK2405 drug for injection, according to a Monday filing with the Shenzhen bourse.The injection is a HER2-targeting antibody-drug conjugate , which has an antibody component that specifically binds to the target antigen on the surface of tumor cells.The product is classified under Registration Category 1 for therapeutic biological products and is used to treat advanced malignant solid tumors.The company said preclinical studies showed high specificity and anti-tumor activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300009":"安科生物","BK4585":"ETF&股票定投概念","NETL":"NETLease Corporate Real Estate ETF","ADC":"艾格里房产","BK0060":"抗癌","BK4581":"高盛持仓","BK0042":"基因检测","BK7095":"多种金属与采矿","ADC.AU":"ACDC Metals Ltd","BK0239":"医药制造","BK4231":"零售房地产信托","XBI":"SPDR S&P Biotech ETF","BK4588":"碎股","BK4080":"零售业房地产投资信托","BK0070":"员工持股"},"translate_title":"中国受理安科生物肿瘤药物临床试验申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300009":0.9,"NETL":0.6,"ADC.AU":1,"XBI":1.5,"ADC":1},"content_text":"Anhui Anke Biotechnology (Group) (SHE:300009) has won approval from China's National Medical Products Administration (NMPA) to carry out clinical trials for its AK2405 drug for injection, according to a Monday filing with the Shenzhen bourse.The injection is a HER2-targeting antibody-drug conjugate (ADC), which has an antibody component that specifically binds to the target antigen on the surface of tumor cells.The product is classified under Registration Category 1 for therapeutic biological products and is used to treat advanced malignant solid tumors.The company said preclinical studies showed high specificity and anti-tumor activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669311914","isCrawlerRequest":true}